Building a Strategic Pipeline of High‑Impact Antiviral Assets
Island Pharmaceuticals is a clinical‑stage biotechnology company focused on accelerating the development of antiviral treatments for diseases with significant unmet medical needs, including mosquito‑borne and high‑consequence viral threats.
Transforming Broad‑Spectrum Antiviral Development
Through a differentiated drug repurposing strategy, Island Pharmaceuticals leverages existing clinical data and established regulatory pathways to advance promising antiviral therapies more efficiently. This approach is designed to reduce development risk while accelerating progress toward key clinical and commercial milestones.
Two programs targeting urgent viral infectious diseases
With two advanced antiviral programs, completion of the Phase 2a/b PROTECT dengue trial, positive FDA guidance on the Animal Rule pathway and the potential for Priority Review Vouchers, Island Pharmaceuticals is positioned for multiple near-term clinical, regulatory and operational milestones.
A Dual-Asset Strategy Targeting High-Impact Viral Diseases
Island Pharmaceuticals is progressing two complementary antiviral programs designed to address both widespread and emerging infectious diseases. Together, ISLA-101 and Galidesivir provide a diversified approach, targeting large endemic markets alongside high-consequence global health threats.
ISLA-101
Demonstrated activity against flaviviruses (subgroup of arboviruses) in models of infection
- ISLA-101 has demonstrated broad anti-viral activity in in-vitro models
- Demonstrated potent anti dengue-1 activity in in-vitro models using fresh human cells
- Protective in dengue fever and Zika in animal models
- Shown to prevent death in 70% of subjects in extremely lethal animal models
- Increasing concentrations of ISLA-101 prevent death induced by an otherwise lethal dengue fever infection
- 48 human clinical studies completed in other indications
- Demonstrated efficacy in prophylactic and treatment cohorts in Phase 2a PROTECT clinical trial
Galidesivir
Galidesivir is a broad-spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats through a well-supported and strategically advanced development pathway.
- Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and yellow fever.
- It is a nucleoside analog that mimics adenosine triphosphate (ATP) and inhibits viral RNA synthesis, allowing broad activity against many RNA viruses.
- Robust development history with over US$70m in funding to-date from US government
- Potential to leverage FDA’s Animal Rule to fast-track approval in Marburg
- Preclinical data showed 100% survival in non-human primates challenged with Marburg or Ebola viruses when administered shortly after infection.
